LCTX Lineage Bio: Forward P/S Multiple

Lineage Corp (LCTX) - corporate logo

Does the laboratory operational format of Lineage Cell Therapeutics (LCTX) impact the environment? The answer lies in the creation of precise cryogenic biomaterial delivery networks that support profitability. This forward price-to-sales chart confirms this success, with the metric standing at 19.00. This price action underscores the company's commitment to restoring spinal cord tissue and vision through regenerative medicine.

lineagecell.com - LCTX Projected Price to Revenue (period 07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Lineage Corp (LCTX)

- current price and projected stock value:
Stock Price Lineage Cell Therapeutics, Inc.|LCTX - Average Forecast Price
- company stock capitalization data:
Market Capitalization Lineage Corp|LCTX - Enterprise Value
- issuer book value statistics:
Book Value per Share Lineage Cell Therapeutics|LCTX - Book Value of Business|Market Capitalization to Book Value Ratio lineagecell.com|LCTX - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Lineage Cell Therapeutics|LCTX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Lineage Cell Therapeutics|LCTX - Company Total Debt|Debts to Book Capitalization Lineage Corp|LCTX - Long-Term Debt|Company Short-Term Debt Lineage Cell Therapeutics|Quick Liquidity lineagecell.com
- financial results and valuation multiples details:
LCTX - Company Net Income|Future Profit Lineage Cell Therapeutics|LCTX - Company Value to Net Income|Projected Price to Earnings Lineage Bio|LCTX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Lineage Corp|LCTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Lineage Cell Therapeutics|LCTX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months lineagecell.com|LCTX - Earnings per share increase in current year|Earnings growth forecast for next year Lineage Cell Therapeutics
- revenue and sales proceeds data:
LCTX - Revenue and Sales Volume|Company Projected Revenue Lineage Cell Therapeutics, Inc.|LCTX - Price-to-Sales Ratio|Forward P/S Multiple Lineage Corp
Analysis of all company metrics:Lineage Cell Therapeutics, Inc. LCTX
Manufactured products of Lineage Corp

To find a balance between cost and business quality, use the forward P/S ratio, which correlates current market capitalization with updated revenue expectations, reflecting the dynamics of market risks. In the case of Lineage Cell Therapeutics (LCTX), the company's projected P/S demonstrates how the market values the commercialization potential of cell therapy for macular dystrophy, accounting for the operational costs priced in and the upcoming scaling of clinical trials.

Competitor analysis

Forward P/S Multiple MESO (Mesoblast)|Surrozen Inc (SRZN) - Market Cap to Future Revenue Ratio|Cryo-Cell International Inc - Forward P/S Multiple|FBLG - Forward P/S Multiple|LGVN: Forward P/S Multiple|Projected Price to Revenue BioRestorative Therapies, Inc. BRTX|CELZ (Creative Medical Technology Holdings, Inc.) - Forward P/S Multiple